 CAMBRIDGE, Mass., May 14, 2021 GLOBE NEWSWIRE -- Praxis Precision Medicines, Inc. NASDAQ: PRAX, a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system CNS disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences: 